Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFI-402257 in Advanced Solid Tumors
NCT02792465Phase 1Completed
- Sponsor
- University Health Network
- Start
- Nov 2016
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of luvixasertib in solid tumor and breast cancer (3 cohorts), sponsored by University Health Network. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Nov 2016; status: completed.
02
Drugs
luvixasertib
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT02792465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792465.